Compare Incyte Corporation (INCY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Under Armour Inc Class A — how do they compare? Incyte Corporation trades at $117.55 (market cap $23.11B), while Under Armour Inc Class A trades at $7.24 (market cap $3.07B). The key difference: Incyte Corporation is far larger — about 7.5× Under Armour Inc Class A's market cap, and Incyte Corporation is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| INCY | UAA | |
|---|---|---|
Market Cap | $23.11B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $8.14 |
52-Week Low | $67.38 | $4.17 |
Enterprise Value | $19.13B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Under Armour (UAA) trades at $7.28, down 2.02% amid mixed signals. The stock shows technical bullish momentum with strong moving average support, but faces fundamental challenges including a net loss of $201.27 million in 2025 and negative profit margins. Recent earnings showed Q4 2025 beat expectations but Q1 2026 missed, while the company maintains international growth momentum despite North American weakness.
The outlook remains cautious with analyst consensus price target of $5.96 below current levels. Investment opportunity exists in international expansion and DTC growth, but risks include persistent North American weakness, margin pressure, and negative cash flow trends that could pressure shareholder value in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
